TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic plaque psoriasis that has been present for more than 6 months and involves at least 10% Body Surface Area (BSA).~* Baseline LS-PGA score of moderate or greater severity.~* Weight \<= 125 kg (276 lb) and a BSA \<= 2.5 m\^2.~Exclusion Criteria:~* Clinically significant flare of psoriasis during the 12 weeks before enrollment.~* Guttate, erythrodermic, palmoplantar, or pustular (von Zumbusch) psoriasis~* Orally administered systemic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks before enrollment.~* Prior administration of a biologic agent/monoclonal antibody within 12 weeks before enrollment or 5 half-lives of the agent, whichever is greater.~* Prior otelixizumab, OKT®3, or teplizumab.~* Treatment within the last 30 days with a non-biologic drug or device that has not received regulatory approval for any indication at the time of study entry or are unwilling to forgo experimental treatment other than teplizumab during this study.~* Treatment with live vaccine within 8 weeks before enrollment or during study; vaccination with an antigen or killed organism during the study, within 8 weeks before enrollment, or 8 weeks after dosing.~* Evidence of active infection.~* Positive IgM test for hepatitis A.~* History of or positive test for hepatitis B, C, or D.~* History of or positive test for HIV.~* Are immunocompromised, have had recent or current serious systemic or local infection, clinical or radiological evidence of active tuberculosis, or evidence of latent TB infection.~* History of chronic liver disease, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or epilepsy.~* Current serious or unstable illnesses or allergies.~* Clinically significant laboratory abnormalities.~* Presence of serological reactivity to teplizumab (in subjects previously treated with therapeutic antibodies).~* Clinically significant ECG abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- teplizumab (Type: EXPERIMENTAL): Anti CD-3 monoclonal antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Euthyroid patients with thyroid nodules before operation on the thyroid gland~Exclusion Criteria:~* Hyperthyroidism~* Hypothyroidism

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
- A1 (Type: None): Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
- B (Type: None): Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
- B1 (Type: None): Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All the patients considered as high risk (see above) or undergoing an advanced upper GI procedure (see above) will be included. This is the prospective analysis of the data that is collected and stored in the monitors. We will be using the massimo Pulse oximeter ,masimo acoustic respiratory monitor and Masimo SED line Brain function monitors that allows electronic storage and retrieval of information.~* Postprocedure analysis of the data will not influence the patient care.~Exclusion Criteria:~* Any patient who cannot give a valid consent will be excluded~* Children~* Pregnant women~* Fetuses and/or Neonates~* Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ChloraPrep Versus Betadine for Elective Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo primary total knee arthroplasty~* Age 18 or over~Exclusion Criteria:~* Inability to provide informed consent or to comply with study assessments due to cognitive impairment or geographic distance~* Age 17 or younger~* Allergies to chlorhexadine gluconate or povidone iodine~* Topical antimicrobial use within 14 days of surgery~* Any active dermatoses or open wounds over the operative site~* Any condition requiring antibiotics 14 days prior to arriving for surgery~* Patients with chronic immunosuppression (such as HIV/AIDS)~* Unable to adhere to follow up schedule and treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
- Arm 2 (Type: ACTIVE_COMPARATOR): Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Obesity and Memory, mRNA, Body Composition, Comorbidity Scale

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are at least 18 years of age and undergo bariatric surgery by a LABS certified surgeon~* Previous enrollment in LABS-1 and LABS-2~Exclusion Criteria:~* Informed consent not obtained~* Prior bariatric surgery~* Unlikely to comply with follow-up protocol~* Unable to communicate with local study staff~* Extensive hearing impairment~* Medical conditions known to impact cognitive performance, including past or present history of traumatic brain injury or neurological disorder.~* Non-English speaking~* Inability to withhold caffeine and nicotine 2 hours before each visit, and alcohol 12 hours before each visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2a (Type: None): Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Patients with clinical CL symptoms for less than 6 months with the diagnosis confirmed by microscopic visualisation of Leishmania parasites in skin scrape smear.~* Patients who have given written informed consent.~Exclusion criteria~* Patients presenting with CL lesions located on or within two centimetres of eyes and lips.~* Patients with more than four lesions.~* Lesions, nodules and/or ulcerations with a diameter (ø) of more than 6 cm.~* Patients with persistent lesions for more than 6 months.~* Patients younger than 10 years.~* Patients who are unlikely, unable or unwilling to be available for and comply to regular follow up visits for 6 months.~* Pregnant, and lactating women \<6 months after delivery.~* Patients with uncontrolled medical illnesses.~* Patients with immune disorders, such as HIV/AIDS, or those who are on steroid medication

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HECT-CL (Type: EXPERIMENTAL): HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pain below the neck present for a minimum of one year.~* Diagnosis of at least one of the following:~  * back pain with or without leg pain,~ * post-herpetic neuralgia,~ * complex regional pain syndrome (CRPS) 1 or 2,~ * diabetic neuropathy,~ * or a general neuropathic condition; medically stable and able to undergo surgery for implantation of the drug infusion system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (0mg/day) (Type: PLACEBO_COMPARATOR): Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
- Gabapentin Low (1mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
- Gabapentin Medium (6mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
- Gabapentin High (30mg/day) (Type: ACTIVE_COMPARATOR): Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Transversus Abdominis Plane Block With or Without Magnesium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) rating I-III~* Age 18-75 years old~* Female~* Undergoing elective total abdominal hysterectomy (TAH) with or without uni/bilateral salpingo-oophorectomy (BSO) under general anesthesia with a Pfannenstiel incision~* Admitted to hospital postoperatively (inpatients)~* Competent to provide informed consent~Exclusion Criteria:~* Emergency TAH ± BSO~* ASA IV-V~* Allergy or sensitivity to study-related medications~* Taking any medications that are contraindicated for the use of any of our study drugs~* Midline incision~* Other regional anesthesia technique (e.g. epidural)~* Morbidly Obese (BMI \> 40)~* Incompetent to provide informed consent~* eGFR \< 50~* Impaired liver function (INR \> 1.5)~* Pre-existing chronic pain condition requiring chronic opioid use~* Significant co-existing cardiovascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium (Type: EXPERIMENTAL): Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
- Non-magnesium (Type: ACTIVE_COMPARATOR): Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Group-based Treatment of Overweight and Obesity in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* BMI 30 or over~* BMI over 28 and under 30 with one or more of following: hypertension, prediabetes, type 2 diabetes, coronary heart disease, hyperlipidaemia, liver steatosis, sleep apnoea or polycystic ovary syndrome.~Exclusion Criteria:~* Severe mental illness~* Previous or present eating disorder~* Pregnancy~* Breast feeding~* Serious cancer under treatment~* Use of weight-loss drugs~* Misuse of alcohol or drugs~* Type 1 diabetes~* Not being able to speak/read/write Swedish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group treatment in primary care (Type: EXPERIMENTAL): The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or greater, able to give consent~* DES implantation \< or = 6 months prior to admission~* Undergoing an invasive surgical procedure that will require cessation of clopidogrel therapy for \>48 hours~Exclusion Criteria:~* Age \< 18 years~* Refusal to give consent~* Surgical procedure performed without discontinuation of clopidogrel therapy (or \< 48h of clopidogrel cessation)~* Ongoing anticoagulant therapy other than aspirin (i.e. warfarin, ticlopidine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-small cell lung cancer (need not be newly diagnosed)~* Stage clinical T1 N0 M0 or T2 N0 M0~* NSCLC must be limited to a single lesion~* NSCLC must be peripherally located (\> 2 cm from proximal bronchial tree and \> 1 cm from mediastinal pleura)~* NSCLC must be considered medically inoperable~* Life expectancy greater than 6 months~Exclusion Criteria:~* Pregnant or breastfeeding~* Prior radiation therapy to the lungs or mediastinum~* Prior malignancy in the last 2 years unless treated definitively and disease free or carcinoma in situ or early stage skin cancers that have been definitively treated~* Receiving other study agents or other types of cancer therapy~* Uncontrolled intercurrent illness~* Pacemaker or defibrillator-dependent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SBRT with proton beam radiation (Type: EXPERIMENTAL): 4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Vitamin D Therapy in HCV Treated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV infection (positive HCV Ab more than 6 months)~* Treated with pegylated interferon and ribavirin~Exclusion Criteria:~* Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus~* Previous non response to antiviral therapy.~* Other causes of chronic liver diseases as schistosomiasis, Wilson disease and alcoholic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- HCV patients under treatment (Type: EXPERIMENTAL): Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week
- HCV without Vit D (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:- You must be diagnosed with locally advanced rectal cancer and have chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a standard treatment approach for this disease. Exclusion Criteria:- You are ineligible for this study if you are pregnant or under the age of 18 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Fragmentation Modalities in Femtosecond Laser-assisted Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient aged ≥ 18 years old~* first Femtosecond Laser-assisted Cataract Surgery scheduled~* cataract density ≥ 3 according to the lens opacities classification system (LOCS)~Exclusion Criteria:~* corneal guttata, uncontrolled glaucoma~* shallow depth of anterior chamber~* patient's refusal to participate in the study~* pregnant or breast feeding patient~* patient under legal protection~* no health coverage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 16 pieces fragmentation (Type: EXPERIMENTAL): None
- 8 pieces fragmentation (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Stage II pressure ulcer or greater~2. Patients who consent to participate~3. Patients who can ingest the supplement either orally or per feeding tube~4. Patients who are 21 years of age or older~Exclusion Criteria:~1. Patients with infected wounds~2. Patients with cellulitis, sepsis or osteomyelitis~3. Patients with end-organ failure~4. Patients with poorly controlled diabetes mellitus (HbA1C\>10)~5. Patients who cannot tolerate oral or bolus tube feedings

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Enriched product, dietary supplement (Type: EXPERIMENTAL): Subjects receiving enriched product compared to an unenriched product
- 1 (Type: ACTIVE_COMPARATOR): Subjects not receiving enriched product

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues